<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121769</url>
  </required_header>
  <id_info>
    <org_study_id>Omegaven Expanded Access</org_study_id>
    <nct_id>NCT02121769</nct_id>
  </id_info>
  <brief_title>Omegaven Expanded Access Protocol</brief_title>
  <official_title>Protocol for Patients With Parenteral Nutrition Associated Liver Disease (PNALD) to Access Parenteral Fish Oil (Omegaven®) - Omegaven IND 122375</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's Health System, Boise, Idaho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's Health System, Boise, Idaho</source>
  <brief_summary>
    <textblock>
      Omegaven is an intravenous fat emulsion (IFE) comprised of omega-3 fatty acids derived from&#xD;
      fish oil. It will be used in an open label compassionate use treatment protocol, as an&#xD;
      alternative to soybean oil (omega-6), as the sole IFE source of parenteral nutrition in an&#xD;
      effort to reduce and/or reverse parenteral nutrition associated liver disease. The study will&#xD;
      evaluate the safety and efficacy of Omegaven use in pediatric patients with PN dependence and&#xD;
      PNALD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Parenteral Nutrition Associated Liver Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven</intervention_name>
    <description>10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients will be PN dependent (unable to meet nutritional needs solely by enteral&#xD;
             nutrition) and are expected to require PN for at least another 30 days&#xD;
&#xD;
          -  Parenteral nutrition associated liver disease (PNALD) as defined as a direct bilirubin&#xD;
             of ≥ 2 mg/dL on the last two consecutive bilirubins while on PN. Other causes of liver&#xD;
             disease should be excluded. A liver biopsy is not necessary for treatment.&#xD;
&#xD;
          -  Failed standard/conventional therapies to prevent progression of PNALD.&#xD;
&#xD;
          -  Age newborn to 17 years of age&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to eggs and/or shellfish&#xD;
&#xD;
          -  Female who is pregnant or lactating&#xD;
&#xD;
          -  Severe hemorrhagic disorder&#xD;
&#xD;
          -  Other causes of chronic liver disease (Hepatitis C, Cystic fibrosis, biliary atresia,&#xD;
             and alpha 1 anti-trypsin deficiency,)&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Parent/legally authorized representative is unwilling to consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Tyler Burpee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Gastroenterology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's Pediatric Gastroenterology</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2014</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Luke's Health System, Boise, Idaho</investigator_affiliation>
    <investigator_full_name>Tyler Burpee, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cholestasis</keyword>
  <keyword>short bowel syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

